ArticleJACC. Advances2025
Cryoballoon Ablation in Older Patients With Heart Failure: Insights From a Large-Scale Multicenter Clinical Study.
Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCryoballoon ablation (CBA) achieves satisfactory outcomes in patients with atrial fibrillation (AF). However, its feasibility in older patients with heart failure (HF) remains unclear.
objectivesThis study examined the efficacy and prognosis of CBA in older patients with HF.
methodsAmong 3,655 patients undergoing CBA at 17 institutions, 549 patients (185 with ≥75 years [older], and 364 with <75 years [younger]) diagnosed with HF were analyzed. Recurrence, mortality, and HF hospitalization after CBA between the older and younger groups were compared using Kaplan-Meier curves and Simon-Makuch analyses. Changes in left ventricular ejection fraction (LVEF) on echocardiography and B-type natriuretic peptide levels were evaluated using linear regression analysis. Major procedural complications included stroke, cardiac tamponade, phrenic nerve injury, prolonged hospitalization, and others.
resultsMost (78%) patients had a preserved LVEF of ≥50%. Major procedural complications were similar in the older and younger groups (3.2% vs 4.7%; P = 0.670). The recurrence-free survival and mortality rates were comparable between the 2 groups during a median follow-up period of 21.5 (12.0-37.0) months. The HF hospitalization rate was higher in the older group (4.0 vs 1.5 per 100 patient-years; P = 0.008). In the older group, LVEF and B-type natriuretic peptide levels improved after ablation (from 57.4% to 60.0%, and 173 [113-292] to 87.8 [42-218] pg/mL). AF recurrence and HF hospitalization were closely linked, with most hospitalizations occurring after a year postablation.
conclusionsCBA for AF in older patients with HF is feasible and improves cardiac parameters; however, specific care is required owing to this population's unique characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.